An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy(Millennium Engineering and Integration (United States)), Steven Langston(Millennium Engineering and Integration (United States)), Allison Berger(Takeda (United States)), Amanda Doucette(Millennium Engineering and Integration (United States)), Christopher F. Claiborne(Roche (Switzerland)), Lawrence R. Dick(Millennium Engineering and Integration (United States)), Anna R. Lublinsky(Millennium Engineering and Integration (United States)), Gabriel S. Weatherhead(Millennium Engineering and Integration (United States)), Mansoureh Rezaei(Millennium Engineering and Integration (United States)), James E. Brownell(AstraZeneca (United States)), Stéphane Peluso(Infinity Pharmaceuticals (United States)), Michael D. Sintchak(Millennium Engineering and Integration (United States)), Štěpán Vyskočil(Scripps Research Institute), Edward J. Olhava(Millennium Engineering and Integration (United States)), Stephen Critchley(Millennium Engineering and Integration (United States)), Joseph B. Bolen(Bristol-Myers Squibb (United States)), Mark Rolfe(Unknown), Michael A. Milhollen(Millennium Engineering and Integration (United States)), Tina Talreja(Millennium Engineering and Integration (United States)), James M. Gavin(Millennium Engineering and Integration (United States)), Courtney Cullis(Millennium Engineering and Integration (United States)), Usha Narayanan(Millennium Engineering and Integration (United States)), Kristine Burke(Millennium Engineering and Integration (United States)), Hirotake Mizutani(Millennium Engineering and Integration (United States)), Jeffrey Gaulin(Millennium Engineering and Integration (United States)), James Garnsey(Millennium Engineering and Integration (United States)), Peter G. Smith(Ollscoil na Gaillimhe – University of Galway), Rachel E. Gershman(Millennium Engineering and Integration (United States)), Jie Yu(KU Leuven), Julie Zhang(Millennium Engineering and Integration (United States)), Michael P. Thomas(Millennium Engineering and Integration (United States)), Alice McDonald(Millennium Engineering and Integration (United States)), Tary Traore(Millennium Engineering and Integration (United States)), Sharmila Adhikari(Millennium Engineering and Integration (United States)), David P. Cardin(Millennium Engineering and Integration (United States))
Cited by 1,991
Related Papers
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|The Lancet Oncology|2018|614
Carbon-dot-supported atomically dispersed gold as a mitochondrial oxidative stress amplifier for cancer treatment
|Nature Nanotechnology|2019|598
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
|Nature Reviews Drug Discovery|2010|554
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
|Molecular Cell|2010|461
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
|Nature Medicine|2018|453